Pulmonary Arterioplasty With Decellularized Allogeneic Patches

Hopkins, Richard A.; Lofland, Gary K.; Marshall, Jennifer; Connelly, Diana; Acharya, Gayathri; Dennis, P.A.; Stroup, Richard E.; McFall, Chris; O’Brien, James E.

doi:10.1016/j.athoracsur.2013.12.005

Cited by 16 publications

(20 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Revising the literature, many authors reported the decellularization of human umbilical cord artery (HUA) [179,182,183,184,185,186,187,188], femoral artery [189], pulmonary artery [71], internal mammary artery [190,191], arteries of the hand dorsum [15], and aortae [192,70] achieving good results in terms of structural and mechanical characteristics.…”

Section: Vesselsmentioning

confidence: 99%

“…Other arteries decellularization methods were based on a single freeze–thaw cycle, incubation in Tris buffer and low concentration SDS followed by treatment with DNase/RNase, as described for femoral arteries [189]; sodium lauroyl sarcosinate and a recombinant endonuclease to decellularize the pulmonary artery [71]; detergent-based methods appealing to SDS solution or Triton X-100 followed by SDS to treat mammary arteries [190,191]; dH 2 O, trypsin/EDTA, and Triton X-100/ammonium hydroxide for arteries of the hand dorsum [15]; and the aorta was processed using CHAPS, SDS, and then treated with endothelial cell growth medium-2 with fetal bovine serum [192] or SDS and DNase-I [70].…”

Section: Vesselsmentioning

confidence: 99%

“…To date, a commercially available product based on allogenic pulmonary artery patch exists (i.e., MatrACELL; Life-Net Health, Inc., Virginia Beach, VA, USA). Revising the literature, two clinical trials considered its use for the reconstruction of right ventricular outflow tract [70] as well as for congenital cardiac reconstruction [71] (Table 1)—in both cases, the device did not cause adverse events or failures. Moreover, both human acellular iliac or mammary artery have been also adopted for clinical use.…”

Section: Vesselsmentioning

confidence: 99%

See 2 more Smart Citations

Tissue-Engineered Grafts from Human Decellularized Extracellular Matrices: A Systematic Review and Future Perspectives

Porzionato

Stocco

Barbon

et al. 2018

IJMS

258

191

View full text Add to dashboard Cite

Tissue engineering and regenerative medicine involve many different artificial and biologic materials, frequently integrated in composite scaffolds, which can be repopulated with various cell types. One of the most promising scaffolds is decellularized allogeneic extracellular matrix (ECM) then recellularized by autologous or stem cells, in order to develop fully personalized clinical approaches. Decellularization protocols have to efficiently remove immunogenic cellular materials, maintaining the nonimmunogenic ECM, which is endowed with specific inductive/differentiating actions due to its architecture and bioactive factors. In the present paper, we review the available literature about the development of grafts from decellularized human tissues/organs. Human tissues may be obtained not only from surgery but also from cadavers, suggesting possible development of Human Tissue BioBanks from body donation programs. Many human tissues/organs have been decellularized for tissue engineering purposes, such as cartilage, bone, skeletal muscle, tendons, adipose tissue, heart, vessels, lung, dental pulp, intestine, liver, pancreas, kidney, gonads, uterus, childbirth products, cornea, and peripheral nerves. In vitro recellularizations have been reported with various cell types and procedures (seeding, injection, and perfusion). Conversely, studies about in vivo behaviour are poorly represented. Actually, the future challenge will be the development of human grafts to be implanted fully restored in all their structural/functional aspects.

show abstract

Section: Vesselsmentioning

confidence: 99%

Section: Vesselsmentioning

confidence: 99%

Section: Vesselsmentioning

confidence: 99%

See 1 more Smart Citation

Tissue-Engineered Grafts from Human Decellularized Extracellular Matrices: A Systematic Review and Future Perspectives

Porzionato

Stocco

Barbon

et al. 2018

IJMS

258

191

View full text Add to dashboard Cite

show abstract

“…The introduction of foreign antigens can potentially cause an immune response that leads to valve calcification and structural deterioration over time. This problem is 86 In this study 13 of the original 118 patients had hypoplastic tissue growth in the vicinity of the patch without overt rapid failures. Although many patients have been successfully treated with Syner-Graft products, case reports of rapid graft failure persist.…”

Section: Biologic Materialsmentioning

confidence: 74%

Regenerative Materials for Surgical Reconstruction: Current Spectrum of Materials and a Proposed Method for Classification

Sharma

Faubion

Dietz

2019

Mayo Clinic Proceedings

View full text Add to dashboard Cite

Chronic wound management is an enormous economic strain and quality-of-life issue for patients. Current treatments are ineffective or expensive and invasive. Materials (native and artificial) can act as the basis to enhance wound repair but often fall short of complete healing. The therapeutic index of materials have often been enhanced by combining them with drug or biologic elution technologies. Combination of materials with living drugs (cells) presents a new paradigm for enhancing therapy. Cell material interaction and therapeutic output will depend on variables ascribed to the living drug as well as variables ascribed to the underlying matrix. In this article, we review medical matrices currently approved by the US Food and Drug Administration (FDA) that would likely be the first generation of materials to be used in this manner. Currently there are hundreds of different materials on the market. Identification of the right combinations would benefit from a classification scheme to group materials with similar composition or derivation. We provide a classification scheme and FDA documentation references that should provide researchers and clinicians a starting point for testing these materials in the laboratory and rapidly transitioning cell therapies to the bedside.

show abstract

“…No degenerative events were reported during follow up, apart from restricted cases of narrowing of the juxtaductal region, without involvement of the implanted graft or stenosis. These results were particularly significant when retrospectively compared with a similar cohort of patients treated with conventional patches in synthetic material, as PTFE, and with cryopreserved pulmonary allografts (14% patch failure) (216). Interestingly, even if not properly a cardiovascular application, human decellularized vessels were effectively applied as dialysis access in 60 patients (217).…”

Section: Clinical Applicationsmentioning

confidence: 98%

Bioengineered tissue solutions for repair, correction and reconstruction in cardiovascular surgery

Iop¹,

Palmosi²,

Sasso³

et al. 2018

J. Thorac. Dis.

View full text Add to dashboard Cite

The treatment of cardiac alterations is still nowadays a dramatic issue in the cardiosurgical practice. Synthetic materials applied in this surgery have failed in their long-term therapeutic efficacy due to low biocompatibility and compliance, especially when used in contractile sites. In order to overcome these treatment pitfalls, novel solutions have been developed based on biological tissues. Patches in pericardium, small intestinal submucosa, as well as engineered tissues of myocardium, heart valves and blood vessels have undergone a large preclinical investigation in regenerative medicine studies. Clinical translation has been started or reached by several of these new bioengineered treatment alternatives. This review will describe the preclinical and clinical experiences realized so far with the application of biological tissues in cardiovascular surgery. It will depict the progressive steps realized in the evolution of this research, as well as it will point out the challenges yet to face in order to generate the ideal biomaterial for cardiovascular repair, corrective and reconstructive surgery.

show abstract

Pulmonary Arterioplasty With Decellularized Allogeneic Patches

Cited by 16 publications

References 25 publications

Tissue-Engineered Grafts from Human Decellularized Extracellular Matrices: A Systematic Review and Future Perspectives

Tissue-Engineered Grafts from Human Decellularized Extracellular Matrices: A Systematic Review and Future Perspectives

Regenerative Materials for Surgical Reconstruction: Current Spectrum of Materials and a Proposed Method for Classification

Bioengineered tissue solutions for repair, correction and reconstruction in cardiovascular surgery

Contact Info

Product

Resources

About